In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins

Food Chemistry

Volumn 136, Issue 2, 2013, Pages 758-764

  Velarde Salcedo, Aída J ^a,b   Barrera Pacheco, Alberto ^a   Lara González, Samuel ^a   Montero Morán, Gabriela M ^a   Díaz Gois, Agustín ^c   González De Mejia, Elvira ^b   Barba De La Rosa, Ana P ^a  

^a INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Centros de Salud   (Mexico)

Author keywords

Amaranthus hypochondriacus; Diabetes; Dipeptidyl peptidase IV; Docking modeling; Encrypted peptides

Indexed keywords

AMARANTH SEEDS; AMARANTHUS; BENEFICIAL EFFECTS; BINDING MODES; BIOACTIVE COMPOUNDS; BLACK BEANS; CATALYTIC SITES; DIMER FORMATION; DIPEPTIDYL PEPTIDASE IV; DOCKING MODELS; DOSE-DEPENDENT MANNER; ENZYMATIC DIGESTIONS; FUNCTIONAL FOODS; GASTROINTESTINAL DIGESTION; HUMAN HEALTH; IN-SILICO; IN-VITRO; INSULIN SECRETION; MOLECULAR LEVELS; NATURAL SUBSTRATES; TRYPTIC DIGESTION;

BINDING ENERGY; DOCKING; ENZYMES; MEDICAL PROBLEMS;

PEPTIDES;

AMARANTH; DIMER; DIPEPTIDYL PEPTIDASE IV; GLOBULIN; GLUTENIN; INCRETIN; INSULIN;

AMARANTHUS; AMARANTHUS HYPOCHONDRIACUS; ARTICLE; BLACK BEAN APHID; COMPUTER MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DIMERIZATION; DOSE RESPONSE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; HYDROLYSIS; IC 50; INSULIN RELEASE; MOLECULAR DOCKING; PROTEIN SECRETION; SOYBEAN; WHEAT;

AMARANTHUS; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; DIGESTION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYDROLYSIS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDES; PLANT PROTEINS; SEEDS; SWINE;

AMARANTHUS CAUDATUS; AMARANTHUS HYPOCHONDRIACUS; GLYCINE MAX; TRITICUM AESTIVUM;

EID: 84866883091     PISSN: 03088146     EISSN: 18737072     Source Type: Journal    
DOI: 10.1016/j.foodchem.2012.08.032     Document Type: Article

References (61)

1. B. Ahrén The future of incretin-based therapy: Novel avenues - novel targets Diabetes, Obesity and Metabolism 1 2011 158 166
2. L. Alvarez-Jubete, E.K. Arendt, and E. Gallagher Nutritive value and chemical composition of pseudocereals as gluten-free ingredients Trends in food Science & Technology 21 2010 106 113
3. A.P. Barba de la Rosa, A. Barba-Montoya, P. Martínez-Cuevas, B. Hernández-Ledesma, M.F. León-Galván, and A. De León-Rodríguez Tryptic amaranth glutelin digests induce endothelial nitric oxide production through inhibition of ACE: Antihypertensive role of amaranth peptides Nitric oxide 23 2010 106 111
4. A.P. Barba de la Rosa, J. Gueguen, O. Paredes-López, and G. Viroben Fractionation procedures, electrophoretic characterization, and amino acid composition of amaranth seed proteins Journal of Agricultural and Food Chemistry 40 1992 931 936
5. A.P. Barba de la Rosa, A. Herrera-Estrella, Sh. Utsumi, and O. Paredes-López Molecular characterization, cloning and structural analysis of a cDNA encoding an amaranth globulin Journal of Plant Physiology 49 1996 527 532
6. R.K. Campbell Fate of the beta-cell in the pathophysiology of type 2 diabetes Journal of the American Pharmacists Association 49 2009 S10 S15
7. S.R. Comeau, D.W. Gatchell, S. Vajda, and C.J. Camacho ClusPro: A fully automated algorithm for protein-protein docking Nucleic Acids Research 32 2004 W96 W99
8. S.L. Conarello, L. Zhihua, J. Ronan, R.S. Roy, L. Zhu, and G. Jiang Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proceedings of the National Academy of Sciences, USA 100 2003 6825 6830
9. M.C. Condés, A.A. Scilingo, and M.C. Añón Characterization of amaranth proteins modified by trypsin proteolysis. Structural and functional changes LWT-Food Science and Technology 42 2009 963 970
10. R.A. DeFronzo Paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
11. D.H. Dewar, M. Amato, H.J. Ellis, E.L. Pollock, N. Gonzalez-Cinca, and H. Wieser The toxicity of high molecular weight glutelin subunits of wheat to patients with celiac disease European Journal of Gatroenterologoy & Hepatology 18 2006 483 491
12. D.J. Drucker Incretin-based therapy and the quest for sustained improvements in β-cell health Diabetes Care 34 2011 2133 2135
13. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of COOT Acta Crystallographica D 66 2010 486 501
14. K. Erdmann, B.W.Y. Cheung, and H. Schröder The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease The Journal of Nutritional Biochemistry 19 2008 643 654
15. J. Gerich DPP-4 inhibitor: What may be the clinical differentiators? Diabetes Research and Clinical Practice 90 2010 131 140
16. B.F. Gibbs, A. Zougman, R. Masse, and C. Mulligan Production and characterization of bioactive peptides from soy hydrolysate and soy-fermented food Food Research Intermational 37 2004 123 131
17. E. Gonzalez de Mejia, C. Martinez-Villaluenga, M. Roman, and N.A. Bringe Fatty acid synthase and in vitro adipogenic response of human adipocytes inhibited by α and α' subunits of soybean β-conglycinin hydrolysates Food Chemistry 119 2010 1571 1577
18. H. Hiramatsu, K. Kyono, Y. Higashiyama, C. Fukushima, H. Shima, and S. Sugiyama The structure and function of human dipeptidil peptidase IV, possessing a unique eight-bladed β-propeller fold Biochemical and Biophysical Research Communications 302 2003 849 854
19. J.J. Holst, F.K. Knop, T. VilsbOll, T. Krarup, and S. Madsbad Loss of incretin effect is a specific, important, and early characteristic of Type 2 Diabetes Diabetes Care 34 2011 S251 S257
20. B. Huisamen, A. Genis, E. Marais, and A. Lochner Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats Cardiovascular Drugs and Therapy 25 2001 13 20
21. N. Inoue, K. Nagao, K. Sakata, N. Yamano, P.E. Gunawardena, and S.Y. Han Screening of soy protein-derived hypotriglyceridemic di-peptides in vitro and in vivo Lipids in Health and Disease 10 2011 85
22. H.J. Jeong, J.R. Lee, J.B. Jeong, and J.H. Park The cancer preventive peptide lunasin from wheat inhibits core histone acetylation Cancer Letters 255 2007 42 48
23. G.M. Keating Vildagliptin. A review of its use in type 2 diabetes mellitus Drugs 70 2010 2089 2112
24. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacological Reviews 60 2008 470 512
25. K. Kos, A.R. Baker, M. Jernas, A.L. Harte, J.C. Clapham, and J.P. ÓHare DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue Diabetes, Obesity & Metabolism 11 2009 285 292
26. D.Y. Kwon, J.W. Daily III, H.J. Kim, and S. Park Antidiabetic effects of fermented soybean products on type 2 diabetes Nutrition Research 30 2010 1 13
27. I.M.E. Lacroix, and E.C.Y. Li-Chan Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach Journal of Functional Foods 4 2012 403 422
28. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 217 1970 680 685
29. R.A. Laskowski PDBsum new things Nucleic Acids Research 37 2009 D355 D359
30. H.E. Liang, and C. Woodward Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design Protein Science 7 1998 1884 1897
31. E.C.Y. Li-Chan, S.L. Hunag, C.L. Jao, K.P. Ho, and K.C. Hsu Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors Journal of Agricultural and Food Chemistry. 60 2012 973 978
32. N. London, B. Raveh, E. Cohen, G. Fathi, and O.Â. Schueler-Furman Rosetta FlexPepDock web server-high resolution modeling of peptide-protein interactions Nucleic Acids Research 39 2011 W249 W253
33. E. Maldonado-Cervantes, H.J. Jeong, M.F. León-Galván, A. Barrera-Pacheco, A. De León-Rodríguez, and E. González de Mejía Amaranth lunasin-like peptide internalizes into the cell nucleus and inhibits chemical carcinogen-induced transformation of NIH-3T3 cells Peptides 31 2010 1635 1642
34. E. Matteucci, and O. Giampietro Dipeptidyl peptidase-4 inhibition: Linking chemical properties to clinical safety Current Medicinal Chemistry 18 2011 4753 4760
35. N. McGough, and J.H. Cummings Coeliac disease: A diverse clinical syndrome caused by intolerance of wheat, barley and rye The Proceedings of the Nutrition Society 64 2005 434 450
36. R. Mentlein Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regulatory peptides 85 1999 9 24
37. N.P. Möller, K.E. Scholz-Ahrens, N. Roos, and J. Schrezenmeir Bioactive peptides and proteins from foods: Indication for health effects European Journal of Nutrition 47 2008 171 182
38. H. Motoi, and T. Kodama Isolation and characterization of angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate Nahrung/Food 47 2003 354 358
39. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications The American Journal of Medicine 124 2011 S3 S18
40. M.A. Nauck, and I. Vardarli Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure Journal of Diabetes Investigation 1 2010 24 36
41. J.R. Petrie, E.R. Pearson, and C. Sutherland Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology Biochemical Pharmacology 81 2011 471 477
42. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, and E.C. Meng UCSF chimera - A visualization system for exploratory research and analysis Journal of Computational Chemistry 25 2004 1605 1612
43. J. Rahfeld, M. Schierhorn, B. Hartrodt, K. Neubert, and J. Heins Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochimica et Biophysica Acta 29 1991 314 316
44. R. Reynoso-Camacho, M. Ramos-Gomez, and G. Loarca-Piña Bioactive components in common beans (Phaseolus vulgaris) R.G. Guevara-González, I. Torres-Pacheco, Advances in Agricultural and Food Biotechnology 2006 Signpost Kerala India 217 236
45. A. Roy, A. Kucukural, and Y. Zhang I-TASSER: A unified platform for automated protein structure and function prediction Nature Protocols 5 2010 725 738
46. A.G.P. Samaranayaka, and E.C.Y. Li-Chan Food-derived peptidic antioxidantas: A review of their production, assessment, and potential applications Journal of Functional Foods 3 2011 229 254
47. J. Schymkowitz, J. Borq, F. Stricher, R. Nys, F. Rousseau, and L. Serrano The FoldX web server: An online force field Nucleic Acids Research 1 2005 382 388
48. Y. Seino, M. Fukushima, and D. Yabe GIP and GLP-1, the two incretin hormones: Similarities and differences Journal of Diabetes Investigation 1 2010 8 23
49. C. Silva-Sánchez, A.P. Barba de la Rosa, M.F. León- Galván, B.O. de Lumen, A. De León-Rodríguez, and E.G. de Mejía Bioactive peptides in amaranth (Amaranthus hypochondriacus L.) seeds Journal of Agricultural and Food Chemistry 56 2008 1233 1240
50. I. Siró, E. Kápolna, B. Kápolna, and A. Lugasi Functional food. Product development, marketing and consumer acceptance. A review Appetite 51 2008 456 467
51. M. Stephan, A. Radicke, S. Leutloff, A. Schimiedl, R. Pabst, and S. von Hörsten Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: Possible implications for the hypothalamic neuropeptidergic system Behavioral Brain Research 216 2011 712 718
52. P.N. Surampudi, J. John-Kalarickal, and V.A. Fonseca Emerging concepts in the pathophysiology of type 2 diabetes mellitus The Mount Sinai Journal of Medicine 3 2009 216 226
53. M.R. Tandag-Silvas, C.C. Cabanos, L. Carrazco-Peña, A.P. Barba de la Rosa, J.A. Osuna-Castro, and S. Utsumi Crystal structure of a major seed storage protein, 11S proglobulin, from Amaranthus hypochondriacus Insight into its physico-chemical properties Food Chemistry 2012 10.1016/j.foodchem.2012.04. 135
54. M. Uchida, Y. Ohshiba, and O. Mogami Novel dipeptidyl peptidase-4-inhibiting peptide derived from b-lactoglobulin Journal of Pharmacological Sciences 117 2011 63 66
55. H. Umezawa, T. Aoyagi, K. Ogawa, H. Naganawa, M. Hamada, and T. Takeuchi Diprotins A and B, inhibitors of dipeptidyl peptidase IV (dipeptidyl peptidase-4) inhibitors Peptides 32 1984 385 838
56. F. Van Lanker, A. Adams, and N. De Kimpe Chemical modifications of peptides and their impact on food properties Chemical Reviews 111 2011 7876 7903
57. W. Wang, N.A. Bringe, M.A. Berhow, and E. Gonzalez de Mejia β-conglycinins among sources of bioactives in hydrolysates of different soybean varieties that inhibit leukemia cells in vitro Journal of Agricultural and Food Chemistry 56 2008 4012 4020
58. WHO. (2011). Global status report on noncommunicable diseases 2010. World Health Organization, WHO Press, < www.who.int >.
59. P.E. Wiedeman DPPIV inhibition: Promising therapy for the treatment of type 2 diabetes Progress in Medicinal Chemistry 45 2007 63 109
60. P.E. Wiedeman, and J.M. Trevillayn Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes Current Opinion in Investigational Drugs 4 2003 412 420
61. D.M.T. Yu, T. Yao, S. Chowdhury, N.A. Nadvi, B. Osborne, and W.B. Church The dipeptidyl peptidase IV family in cancer and cell biology The FEBS Journal 277 2010 1126 1144